Titre du document / Document title

Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma

Auteur(s) / Author(s)

NELSON H. ⁽¹⁾ ; KEMP J. P. ⁽²⁾ ; BIELER S. ⁽³⁾ ; WAUGHAN L. M. ⁽³⁾ ; HILL M. R. ⁽³⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ National Jewish Medical and Research Center, Denver, CO, ETATS-UNIS
⁽²⁾ Allergy and Asthma Medical Group and Research Center, San Diego, CA, ETATS-UNIS
⁽³⁾ Dura Pharmaceuticals, Inc., San Diego, CA, ETATS-UNIS

Résumé / Abstract

Study objective: To compare the long-term efficacy and safety of albuterol administration using a a Spiros Inhalation System (Dura Pharmaceuticals; San Diego, CA) dry powder inhaler (DPI) and albuterol (Ventolin; Glaxo Wellcome; Research Triangle Park, NC) administration using a metered-dose inhaler (MDI) in patients with asthma. Materials and methods: This was a phase III, 12-week, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter study of 283 adolescent and adult patients with mild to moderate asthma. The patients were randomized into one of three treatment groups: the Spiros group, who were given 108 μg/actuation of albuterol sulfate equivalent to 90 μg of albuterol base; the MDI group, who were given 90 μg/actuation of albuterol; and the placebo group. Results: Over the length of the study, the Spiros and MDI groups were comparable in all FEV₁ parameters. Both active treatment groups were superior to the placebo group for each FEV₁ parameter at all visits. With the exception of differences at treatment week 0 for the maximum percent change in the FE the duration of effect, and the area under the curve at baseline, there were no statistically significant differences between the Spiros and MDI groups for any FEV₁ parameters. Using a repeated-measures analysis, the FEV₁ parameters at week 0 for the Spiros group were not statistically significantly different from the parameters at weeks 4, 8, and 12. The same analysis effect at week 0 for the MDI group was greater for maximum percent change in the FEV₁ from baseline (weeks 4, 8, and 12) and duration of effect. Adverse events and changes in clinical laboratory values, vital signs, ECG results, and physical examinations were reported with similar incidence in each of the three treatment groups. Conclusion: Both active treatments were superior to the placebo treatment. The Spiros DPI was well tolerated and was as effective as the albuterol MDI in treating patients with moderate asthma.

Revue / Journal Title

Chest   ISSN 0012-3692   CODEN CHETBF 

Source / Source

1999, vol. 115, n^o2, pp. 329-335 (22 ref.)

Langue / Language

Anglais

Editeur / Publisher

American College of Chest Physicians, Northbrook, IL, ETATS-UNIS  (1970) (Revue)

Mots-clés anglais / English Keywords

Asthma ; Inhalation ; Aerosols ; Powder ; Comparative study ; Treatment efficiency ; Tolerance ; Human ; Respiratory disease ; Obstructive pulmonary disease ; Bronchodilator ; β-Adrenergic receptor agonist ; β2-Adrenergic receptor ; Chemotherapy ; Treatment ; Dosage form ;

Mots-clés français / French Keywords

Asthme ; Inhalation ; Aérosol ; Poudre ; Etude comparative ; Efficacité traitement ; Tolérance ; Homme ; Albutérol ; Appareil respiratoire pathologie ; Bronchopneumopathie obstructive ; Bronchodilatateur ; Stimulant β-adrénergique ; Récepteur β2-adrénergique ; Chimiothérapie ; Traitement ; Forme pharmaceutique ;

Mots-clés espagnols / Spanish Keywords

Asma ; Inhalación ; Aerosol ; Polvo ; Estudio comparativo ; Eficacia tratamiento ; Tolerancia ; Hombre ; Aparato respiratorio patología ; Broncopneumopatía obstructiva ; Broncodilatador ; Estimulante β-adrenérgico ; Receptor β2-adrenérgico ; Quimioterapia ; Tratamiento ; Forma farmacéutica ;

Localisation / Location

INIST-CNRS, Cote INIST : 7627, 35400007421903.0090